I am thrilled to note that the Nobel Prize in Chemistry for 2022 was awarded to Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless for the development of Click Chemistry and Bioorthogonal Chemistry.

From the Leader's Desk


I am thrilled to note that the Nobel Prize in Chemistry for 2022 was awarded to Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless for the development of Click Chemistry and Bioorthogonal Chemistry.


Syngene has implemented both approaches in research on heterobifunctional molecules, peptides and ADCs. The use of this chemistry in cells has also enabled us to develop novel imaging probes for visualization of the targets inside the cell through fluorescent labelling.


In this edition of our newsletter, we spotlight Syngene’s peptide synthesis services. Also included, is our degrader toolbox, which provides an end-to-end view of our PROTAC capabilities.


In the case study section on Safety-Tox studies, don't miss the detailed testimonial provided by Cytopeutics for the support we provided in advancing their cell therapy drug to the clinic.


The poster section showcases how Syngene scientists have used an informatics-driven target prioritization strategy to identify an untargeted member of the CEACAM family as a therapeutic target for pancreatic cancer.


Lastly, I am delighted to announce that Syngene won the Asia Pacific Biologics CMO Excellence Awards 2022 for Quality.


Happy reading!

Best Wishes,

Kenneth J. Barr, Ph.D.
Senior Vice President, Discovery Services
Syngene International Ltd.

In the Spotlight


Peptides synthesis services: Delivering high-quality peptides from milligram to gram scale


Syngene offers high-throughput synthesis of peptide libraries, allowing clients to quickly screen targets. Our team can generate up to 50-mer linear peptides and develop cysteine-rich disulphide-bridged peptides, leading to improved peptide stability. Our experience includes designing and synthesizing peptide derivatives and generating conformationally constrained peptides that have enhanced biophysical properties.

Protein Degradation at Syngene


Five questions that determine the success of your PROTAC programs

 


Learn the challenges in developing targeted degraders and how Syngene’s extensive experience can propel your programs forward. We bring extensive experience in not only synthesis but also characterization of PROTACs, molecular glues, and other heterobifunctional molecules, including in vivo DMPK and pharmacological models.

 

 

 

 

Case Study


How Syngene's safety tox package helped Cytopeutics to advance its cell therapy drug to the Clinic


Learn how Cytopeutics partnered with Syngene to conduct in vivo safety and tumorigenicity studies for its Human Mesenchymal Stem Cell (hMSC) product in appropriate animal models (including immunocompromised mice) as per regulatory guidelines. Based on these studies, Cytopeutics went on to receive Malaysia's precedent CTX license under Cell and Gene Therapy for the manufacturing of its hMSCs for clinical and investigational use

Scientific Poster


Profiling CEACAM7 as a potential target for pancreatic cancer



Members of carcinoembryonic antigen cell adhesion molecule (CEACAM) family have been identified as markers for Pancreatic Cancer. Currently, from among 12 CEACAMs, 1, 5 and 6 have antibodies against them in the developmental phases. Find out how our scientists used an informatics-driven target prioritization strategy, to probe and identify an untargeted member of the CEACAM family as a therapeutic target for pancreatic cancer.

 

© 2022, Syngene International Ltd.

Syngene International Ltd. Biocon Park, SEZ,

Bommasandra Industrial Area - Phase-IV Bangalore 560099 India